AZD4573 as Monotherapy or in Combinations with Anti-cancer Agents in Patients with r/r PTCL or r/r cHL

Trial Identifier: D8231C00001
Sponsor: AstraZeneca
NCTID:: NCT05140382
Start Date: December 2021
Primary Completion Date: August 2023
Study Completion Date: February 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
English (Australian) Translation
English (UK) Translation
Spanish (United States) Translation
French Translation
Italian Translation
Korean Translation
Traditional Chinese (Taiwan) Translation

Trial Locations

Country Location
AU Clayton, AU, 3168
AU Melbourne, AU, 3000
AU Nedlands, AU, 6009
FR Besançon, FR, 25000
FR Clermont Ferrand, FR, 63003
FR CRETEIL, FR, 94010
FR Lille Cedex, FR, 59037
FR MONTPELLIER Cedex 5, FR, 34295
GB Headington, GB, 0X3 7LJ
GB London, GB, NW1 2PG
IT Bologna, IT, 40138
IT Napoli, IT, 80131
KR Seoul, KR, 03722
KR Seoul, KR, 05505
KR Seoul, KR, 03080
KR Seoul, KR, 06351
SE Lund, SE, 221 85
SG Singapore, SG, 322605
SG Singapore, SG, 169608
SG Singapore, SG, 119074
TW Kaohsiung City, TW, 83301
TW Taichung, TW, 40447
TW Tainan, TW, 70403
TW Taipei, TW, 100
US, CA Duarte, CA, US, 91010
US, MA Boston, MA, US, 02215
US, NJ Hackensack, NJ, US, 07601
US, TX Houston, TX, US, 77030
US, UT Salt Lake City, UT, US, 84112
US, WA Seattle, WA, US, 98104